Oxford BioMedica | Wikipedia audio article
Channel: wikipedia tts
Date: 2019-01-16

This is an audio version of the Wikipedia Article:
https://en.wikipedia.org/wiki/Oxford_BioMedica


00:00:58 Finance



Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago.

Learning by listening is a great way to:
- increases imagination and understanding
- improves your listening skills
- improves your own spoken accent
- learn while on the move
- reduce eye strain

Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone.

Listen on Google Assistant through Extra Audio:
https://assistant.google.com/services/invoke/uid/0000001a130b3f91
Other Wikipedia audio articles at:
https://www.youtube.com/results?search_query=wikipedia+tts
Upload your own Wikipedia articles through:
https://github.com/nodef/wikipedia-tts
Speaking Rate: 0.8818286981422447
Voice name: en-AU-Wavenet-B


"I cannot teach anybody anything, I can only make them think."
- Socrates


SUMMARY
=======
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of gene-based medicines. It was established in 1995 as a spin out from Oxford University. The lead product is TroVax, a therapeutic cancer vaccine for multiple solid cancers, which is in Phase III development in collaboration with Sanofi-Aventis. TroVax failed in a key kidney cancer test in 2008 which caused a dramatic drop in Oxford BioMedica's share price. The Company’s advanced development pipeline includes treatments for cancer, Parkinson's disease and retinopathy. The company's early stage development pipeline includes preclinical candidates for Stargardt disease, motor neuron disease, spinal muscular atrophy and AIDS.In 2018, Oxford BioMedica's gene therapy for Parkinson's disease became the subject of a commercialization deal with Axovant Sciences.